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Abstract
Background: Uveal melanoma (UM) is the most common intraocular tumor in adults. Despite good primary tumor
control, up to 50% of patients develop metastasis, which is lethal. UM often presents asymptomatically and is
usually diagnosed by clinical examination and imaging, making it one of the few cancer types diagnosed without a
biopsy. Hence, alternative diagnostic tools are needed. Circulating tumor DNA (ctDNA) has shown potential as a
liquid biopsy target for cancer screening and monitoring. The aim of this study was to evaluate the feasibility and
clinical utility of ctDNA detection in UM using specific UM gene mutations.
Methods: We used the highly sensitive digital droplet PCR (ddPCR) assay to quantify UM driver mutations (GNAQ,
GNA11, PLCβ4 and CYSTLR2) in cell-free DNA (cfDNA). cfDNA was analyzed in six well established human UM cell
lines with known mutational status. cfDNA was analyzed in the blood and aqueous humor of an UM rabbit model
and in the blood of patients. Rabbits were inoculated with human UM cells into the suprachoroidal space, and
mutated ctDNA was quantified from longitudinal peripheral blood and aqueous humor draws. Blood clinical
specimens were obtained from primary UM patients (n = 14), patients presenting with choroidal nevi (n = 16) and
healthy individuals (n = 15).
Results: The in vitro model validated the specificity and accuracy of ddPCR to detect mutated cfDNA from UM cell
supernatant. In the rabbit model, plasma and aqueous humor levels of ctDNA correlated with tumor growth.
Notably, the detection of ctDNA preceded clinical detection of the intraocular tumor. In human specimens, while
we did not detect any trace of ctDNA in healthy controls, we detected ctDNA in all UM patients. We observed that
UM patients had significantly higher levels of ctDNA than patients with nevi, with a strong correlation between
ctDNA levels and malignancy. Noteworthy, in patients with nevi, the levels of ctDNA highly correlated with the
presence of clinical risk factors.
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Conclusions: We report, for the first time, compelling evidence from in vitro assays, and in vivo animal model and
clinical specimens for the potential of mutated ctDNA as a biomarker of UM progression. These findings pave the
way towards the implementation of a liquid biopsy to detect and monitor UM tumors.
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Background
Uveal melanoma (UM) is the most common primary in-
traocular malignancy in adults [1–3] and the second
most common form of melanoma after that of the skin
[4]. While rare, with an incidence of 4.2 per million [4],
it is associated with a high mortality rate [3]. Patients
are most commonly treated by globe-preserving plaque
radiation or by enucleation for large tumors [5]. Regard-
less of primary treatment and effective local tumor con-
trol, approximately 50% of patients develop metastasis,
primarily to the liver via hematogenous dissemination
[4]. Liver metastasis is lethal in the majority of patients,
with an estimated 6–12 months survival rate [4].
Predisposing risk factors for UM development include
environmental exposure and intrinsic factors such as the
occurrence of gene mutations (such as GNAQ, GNA11,
BAP1, CYSLTR2, PLCB4) [6–12]. For instance, UM is
characterized by constitutive activation of G protein-
coupled receptor signaling, with a hotspot mutation in ei-
ther G protein subunit alpha Q (GNAQ) or alpha 11
(GNA11). These mutations represent an initiating event in
up to 90% of all UM cases [10, 11]. Less commonly, muta-
tions in cysteinyl leukotriene receptor 2 (CYSLTR2) or
phospholipase C beta 4 (PLCB4) have been reported [13,
14]. Pre-existing nevi in the choroid are reported as poten-
tial precursors of UM [15]. Interestingly, GNAQ/11 muta-
tions have also been detected in these lesions [15],
suggesting that such mutations may be essential but not
sufficient for malignant transformation. Choroidal nevi
are the most common pigmented intraocular lesions, with
a prevalence of 4.6 to 7.9% in the USA [16]. However, be-
cause these lesions are generally asymptomatic and found
on ophthalmic exams performed for other reasons, it is
believed that the true incidence may be much higher.
Generally a nevus remains stable over time [17]; however,
a rate of malignant transformation of 2, 9, and 13% at 1, 5,
and 10 years, respectively, has been reported [18]. Al-
though choroidal nevi are not biopsied, they are clinically
followed for signs of growth or malignant transformation
[18]. Risk factors for malignant transformation include
tumor thickness greater than 2mm, subretinal fluid, visual
symptoms, orange lipofuscin pigment, tumor margin
within 3mm of the optic disc (i.e. peripapillary), ultra-
sonographic hollowness, and halo absence [18].
Moreover and due to the asymptomatic nature of UM,
UM this disease is often detected during a routine
ophthalmology examination, and its diagnosis is based on
ultrasonography [4], making UM one of the few malignan-
cies in which a biopsy is generally not used to confirm the
diagnosis [19]. Detection of the classical presentations of UM
generally gives rise to an accurate diagnosis; however, clinical
diagnosis of nevi that have clinical risk factors that border
onto malignancy becomes a challenge [20]. In addition, over-
lap in the size between small UM and benign choroidal nevi
adds to this challenge [21]. Therefore, having a quantitative
screening method is crucial to differentiate between benign
choroidal nevi and small malignant melanomas, as both
often share several features such as size, color, location, dru-
sen, orange pigment, and subretinal fluid.
While biopsies are generally not used for diagnosis,
they are used in UM lesions for prognostication [19].
Important prognostic factors for metastasis have been
elucidated, such as chromosomal anomalies assessed by
cytogenetics, gene expression profiling, and the presence
of loss of function BAP1 mutations [22]. However, tissue
biopsies, aside from being invasive, provide a static pic-
ture of the tumor, neglecting spatial and temporal het-
erogeneity and do not sample disseminated disease,
circulating tumor cells (CTCs), or micrometastasis [23,
24]. As such, UM remains challenging as it requires ac-
curate profiling, proper interpretation of nevi (as nevi
often share several features with UM [21]) and/or right
risk stratification. Given the high rate of metastasis asso-
ciated with this malignancy, more objective monitoring
is needed to determine the best treatment options. An
alternative approach that does not rely on a biopsy and
that could non-invasively sample tumor-derived material
would be paramount, especially to distinguish high risk
nevi from small UM as well as to detect metastasis.
Liquid biopsy is a minimally invasive approach to de-
tect and monitor disease progression, recurrence and re-
sponse to treatment by investigating/assessing tumor
features using different biofluids, most commonly blood,
as well as other biofluids such as urine [25], saliva [26],
and pleural effusion [27]. In the eye, aqueous and vitre-
ous humors have been proposed as sources of circulating
tumor DNA (ctDNA) in retinoblastoma [28, 29]. Cell-
free DNA (cfDNA) has been widely studied as a liquid
biopsy analyte. ctDNA can be detected within cfDNA
using mutations inherent to a tumor lesion [30]. ctDNA
represents as little as 0.1% of the total cfDNA [31], mak-
ing its detection a challenge. Thus, a highly sensitive and
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specific method is needed not only for diagnosis, but
also for monitoring disease progression. Digital droplet
PCR (ddPCR) detects allele frequencies as low as 0.01%
[32], making it suitable for ctDNA analysis.
Using this highly sensitive assay, we undertook this
study to investigate the feasibility and clinical value of
tracking UM-specific mutated ctDNA.
Material and methods
Cell lines and culture conditions
MP41 and MP46 were purchased from American Type
Culture Collection (ATCC). 92.1 cells were gifted by Dr.
Martine Jager (Leiden University, Netherlands) [33].
MEL270 and OMM2.5 were gifted by Dr. Vanessa Mo-
rales (University of Tennessee). OCM1 was received
from the Institute of Ophthalmology and Visual Sciences
(University of Valladolid). Cells were cultured in RPMI-
1640 (Corning) supplemented with 10% Fetal Bovine
Serum, 10mM HEPES, 2 mM Corning glutaGRO, 1 mM
NaPyruvate, 0.1% 10 U/mL penicillin and 10 μg/mL
streptomycin (all from Corning), and 10 μg/mL insulin
(Roche) in a 37 °C and 5% CO2 atmosphere.
Animal model
Fifteen female New Zealand albino rabbits (Charles
River) were used in accordance with an animal use
protocol (#2018–8028) approved by the Animal Care
Committee at the Research Institute of the McGill Uni-
versity Health Centre (RI-MUHC). Animals were ran-
domly divided into three groups of five rabbits each: (i)
group 1 (labeled G1:R1 to G1:R5), group 2 (labeled G2:
R1 to G2:R5) and group 3 (labeled G3:R1 to G3:G5)
(Fig. 2A). All rabbits were immunosuppressed using
daily intramuscular injections of cyclosporin A (CsA at
15 mg/Kg) (Sandimmune, Novartis), starting 3 days be-
fore cell inoculation and lasting until intraocular tumor
detection by fundoscopy. Following anesthesia using
intramuscular injection of Acepromazine (0.75 mg/Kg),
Ketamine (35 mg/Kg) and xylazine (5 mg/Kg), 1 million
live 92.1 cells (in groups 1 and 2) or MP41 cells (in
group 3) were inoculated into the suprachoroidal space
in the right eye [34]. All rabbits were examined weekly
with fundoscopy (Keeler Vantage Plus Indirect LED Bin-
ocular Opthalmoscope, lens 20D Indirect BIO lens from
Volk Optical) and ultrasound (Master-Vu, Sonomed
Escalon) using drops of tropicamide and phenylephrine
to dilate pupils. No anesthesia or sedation were required.
At fundoscopic detection of UM lesions, CsA doses were
decreased to 10mg/Kg daily in group 1, discontinued in
group 2, or reduced to 5 mg/kg daily in group 3. During
the experiment, all rabbits were monitored daily for CsA
secondary effects (i.e. weight loss, loss of appetite, and
gastrointestinal and respiratory complications). One
rabbit (G3:5) was excluded from our study at week 3
due to early death following serious CsA secondary ef-
fects. Animals were euthanatized by intraperitoneal in-
jection of pentobarbital sodium (120 mg/Kg). After
enucleation, eyes were fixed in 10% phosphate-buffered
formalin (Fisher). Using an DSX100 microscope (Olym-
pus) gross pathology images were obtained. During fun-
doscopy examinations, tumors were measured and
categorized into four categories based on basal diameter:
0 (no tumor formation), 1 (small: < 11 mm), 2 (medium:
11 to 15mm), and 3 (large: > 15mm).
Patient recruitment and categorization
Forty-five participants were enrolled for this study (14
patients diagnosed with primary UM, 16 patients with
choroidal nevi and 15 healthy individuals (controls)) at
the McGill Academic Eye Clinic (MAEC) in accordance
to an approved ethics protocol (MAEC; IRB protocol
#2018–4187) approved by the Review Ethics Board of
the RI-MUHC (Table 2, 3 and 4). The enrolled healthy
individuals had no symptoms or personal history of can-
cer at the time of consent, and no family history of can-
cer. Blood samples were obtained following acquisition
of informed consent.
Patient medical records were retrieved and used to
correlate ctDNA to disease characteristics. UM patients
were classified according to the American Joint Commit-
tee on Cancer (AJCC) classification of UM (Table 3)
[35]. In the UM cohort, no evidence of metastasis was
seen in any patient. Most of the UM patients had under-
went episcleral brachytherapy (plaque radiation) as treat-
ment, except LB36 who had not received any treatment
at the time of blood withdraw (Table 3). Patients with
nevi were categorized according to risk factors for UM:
thickness, presence of subretinal fluid, visual symptoms,
orange pigment, peripapillary, halo, and ultrasono-
graphic hollowness (Table 4) [18].
Blood specimen collection and sample preparation
In the animal model, following anesthesia (as stated
above), 8 mL of peripheral blood was collected via the
central ear artery using EDTA tubes (Becton Dickinson)
at the day of cell inoculation, every 2 weeks from week 4
to 16 after inoculation and at euthanasia. For human do-
nors, 10 mL blood samples were collected from a periph-
eral vein. Blood samples from all UM patients, nine
patients with nevi , and eight control were collected in
PAX gene Blood ccfDNA Tubes (QIAGEN/Becton Dick-
inson). Blood samples from the remaining seven healthy
individuals and seven patients with nevi were collected
in vacutainer tubes containing clot-activation additive
and a barrier gel and left 60 min at room temperature to
isolate serum (Becton Dickinson). Blood samples were
spun at 2000 g for 20 min within 1 h after collection. A
second spin (2000 g for 20 min) was performed to ensure
Bustamante et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:196 Page 3 of 16
for the elimination of contaminating cells. Resultant
plasma/serum were aliquoted and store at − 80 °C until
DNA isolation.
Aqueous humor collection from rabbits
At the time of cell inoculation, at tumor formation
(weeks 5–8), and euthanasia (18–19 weeks), a paracen-
tesis was conducted to withdraw 100–300 uL aqueous
humor from the anterior chamber of rabbits from
groups 1 and 2 using a BD Luer-Lok 1 mL syringe (Bec-
ton Dickinson). The procedure was conducted under
general anesthesia (as stated above) and following topical
application of proparacaine hydrochloride ophthalmic
solution (Alcon).
DNA isolation
Genomic DNA (gDNA) was extracted from all cell lines
using the QIAamp DNA Mini Kit (QIAGEN) according
to the manufacturer’s instructions. cfDNA was recovered
either from: (i) 3 mL cell conditioned medium: 4 × 105
cells were seeded in a T25 flask (Corning), once culture
reached 80% confluency, the medium was renewed. Then,
after 12 h it was collected in 15mL tubes (Falcon) and
spun at 300 g for 5min to eliminate contaminating cells
and cell debris. (ii) 2 mL plasma/serum samples, or (iii)
100–300 μL aqueous humor samples using the QIAamp
Circulating Nucleic Acid (CNA) Kit (QIAGEN). Isolated
DNA was stored in AVE buffer (RNase-free water with
0.04% sodium azide-QIAGEN) in a 25 uL final volume
and quantified using Qubit 2.0 fluorometer with Qubit
dsDNA HS assay reagents (Supplementary Figure 2A-E
and 3A) (Thermofisher Scientific).
Analysis of mutated DNA fragments
To evaluate technical reproducibility, ctDNA was quanti-
fied from 2mL plasma in duplicate using ddPCR. The hot-
spot mutations analyzed were Q209P (c.626 A >C) and
Q209L (c.626 A >T) in GNAQ, Q209P (c.626 A >C) and
Q209L (c.626 A >T) in GNA11, L129Q (c.386 T >A) in
CYSLTR2 and D630Y (c.1888G >T) in PLCB4 (Table 1).
Primers, probes, and synthetic DNA (i.e. gBlock used
as a positive control) were designed by Integrated DNA
technologies (Table 1). Serial dilutions using gBlocks
were performed to obtain the minimum detection of
mutant copies (Supplementary Figure 1). A 20 μL reac-
tion mixture was prepared using 10 μL 2x ddPCR Super-
mix for probes (No UTP) (Bio-Rad), 900 nM forward/
reverse primers, 250 nM hydrolysis probes, 1 ng DNA
sample, and RT-PCR grade water (Invitrogen). DNA
samples were run in triplicates, and the no-template
controls and positive controls were run in duplicates.
Droplets were generated using a QX200 droplet gener-
ator (Bio-Rad), and transferred into a semi-skirted 96-
well PCR plate (Bio-Rad). Using a C100 thermal cycler
(Bio-Rad), PCR reactions were run as follows: 10 min at
95 °C, followed by 50 cycles of 30 s at 95 °C, 1 min at 56–
60 °C (optimized for each primer set (Table 1)), and 30 s
at 72 °C, and finally, 10 min at 98 °C. Using a ramp rate
Table 1 ddPCR primers and probes information for this study
Oligos Annealing Temperature
GNA11-F CTTTCAGGATGGTGGATGT
GNA11-R ACATGATGGATGTCACGTTCT 58 °C
GNA11_A_Allele 5HEX/AC + CGC + TGG + CC/3IABkFQ
GNA11_C_Allele 56-FAM/AC + CGC + GGGCC/3IABkFQ
GNA11_T_Allele 56-FAM/AC + CGC + AGG + CC/3IABkFQ
GNAQ-F CTTGCAGAATGGTCGATGTAG
GNAQ-R GCGCTACTAGAAACATGATAGAG 60 °C
GNAQ_A_Allele 5HEX/CCT + T + T + G + GCCC/3IABkFQ
GNAQ_Q209L_T_Allele 56-FAM/CCT + T + A + G + GCCC/3IABkFQ
GNAQ_Q209P_C_Allele 56-FAM/ACCT+T + G + GGCC/3IABkFQ
PLCb4-F TAACAAACGGCAAATGAGTCG
PLCb4-R CAGCCAGCGTTCCAGAAA 55 °C
PLCB4_D630Y_G_allele 5HEX/CGA + GT + C + G + ATT + CC/3IABkFQ
PLCB4_D630Y_T_allele 56-FAM/CGA + GT + C + T + AT+TC + CA/3IABkFQ
CYSLTR2-F CCTTGTATGTCAACATGTACAGC
CYSLTR2-R GTGAACCATTGCCAGGAAAC 55 °C
CYSLTR2_T_allele 5HEX/TTC + C + T + GA + CCGT/3IABkFQ
CYSLTR2_A_allele 56-FAM/TTC + C + A + GA + CCGT/3IABkFQ
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of 2°C/s. Processed droplets were analyzed in a QX200
Droplet reader (Bio-Rad). Samples with ≤2 mutant drop-
lets were considered as negative for ctDNA. Copies of
target and percentage fractional abundance (%FA),
which refers to the portion of the mutant allele frequen-
cies over the wild type background, were generated by
Quanta Soft software v 1.7.4.
Data analysis
Our data were analyzed using levels of ctDNA (mole-
cules/mL) and %FA. The number of ctDNA molecules
was calculated following a previous reported calculation
[31, 36], where the amount of copies/μL, volume added
to each reaction and amount of plasma/serum are con-
sidered, as well as assuming 3.3 pg corresponded to the
weight of a human haploid.
Graphs and statistical analyses were performed using
Excel or Prism GraphPad Software. Spearman correl-
ation analyses were performed to measure the degree of
association between data outcomes, and comparison
among groups was done by Kruskal-Wallis test. P < 0.05
was considered statistically significant.
Results
Validation of wild type and mutant cfDNA detection in
conditioned medium of human UM cell line cultures
ddPCR, coupled to the noninvasive blood-based liquid bi-
opsy, has been proposed as a promising and accurate
strategy to document rare variant mutations for the moni-
toring of cancer development and progression [32]. By tar-
geting well-known driver mutations that characterize UM,
we performed ddPCR analyses to determine its feasibility
and value for UM patient staging. We assayed serial dilu-
tions of gBlocks that mimic several UM somatic muta-
tions to determine the minimal detection levels of
mutated copies. We were able to detect as little as 0.16,
0.08, 0.09, 0.41, 0.57 and 0.09 [copies/μL] mutated DNA
for GNAQ c.626 A > T, GNAQ c.626 A > C, GNA11 c.626
A > T, and GNA11 c.626 A > C, PLCβ4 c.1888G > T, and
CYSLTR2 c.386 T > A mutations, respectively (Supplemen-
tary Figure 1).
We first sought to determine whether we could detect
cfDNA in a culture system of UM. We used six well estab-
lished human UM cell lines (92.1, MP41, MP46, MEL270,
OMM2.5 and OCM1) with known mutational status to
set up our assay by focusing on mutations at GNAQ and
GNA11. By analyzing genomic DNA (gDNA), we detected
the correct mutation signature in all UM cell lines, as pre-
viously reported, which strengths the validity of our test
(Fig. 1A-C, Supplementary Table 1) [37]. Notably, when
we assessed DNA fragments recovered from cell-free con-
ditioned media of these cell lines, we detected both
GNAQ/11 WT and the correct parental GNAQ/11 muta-
tion (c.626A > C or c.626A > T), respective to the analyzed
cells, indicating the release of different amounts of frag-
mented DNA (i.e. cfDNA) into the culture medium (Fig.
1A-C). In addition, in conditioned media from OCM1, a
known GNAQ/11 wild type cell line, we did not detect any
mutant copies of GNAQ/11 (Fig. 1B) [38]. Together, these
results indicate the feasibility of our assay to accurately
and specifically detect fragmented mutant UM cfDNA
targets.
Blood mutated ctDNA levels correlated with tumor
development and progression in a UM animal model
As we had established the conditions to screen for
cfDNA using the cell culture model, we applied our
assay to assess the utility of GNAQ/11 mutations in de-
tecting ctDNA as a liquid biopsy in vivo. For this pur-
pose, we first took advantage of a human UM rabbit
model that we developed [34]. We used two cell lines
with different driver mutations (i.e. 92.1 and MP41 cells
harboring mutated GNAQ (c.626 A > T) and GNA11
(c.626 A > T), respectively) (Fig. 2A, Supplementary
Table 1). The goal is to insure the potential of screening
for different UM specific mutations in vivo. During the
course of the animal experiments and once ocular tu-
mors were detected by ultrasound and fundoscopy, we
adjusted the dosage of CsA to reduce the adverse effects
associated with the drug (Supplementary Table 1). In
addition, in the cohort of rabbits injected with 92.1 cells,
CsA administration was discontinued in Group 2 to de-
termine the potential of our assay to monitor for disease
progression (i.e. tumor shrinkage) (Fig. 2A).
Rabbits developed detectable subretinal tumors within
4–6 weeks as judged by ultrasound and fundoscopic ex-
aminations (Fig. 2B, Supplementary Table 2). As the
growth of the ocular tumors differed between rabbits,
their sizes at different time points (i.e. 4, 6, 8, 10, 12, 14,
and 16 weeks after cell inoculation and at euthanasia)
were assessed and categorized by a clinical ophthalmolo-
gist into four categories as stated under the methods
section (Fig. 3A-C). In parallel, blood samples were re-
covered to analyze cfDNA patterns (Fig. 2A and 3 A-D).
Total cfDNA ranged from 10.1 ng to 189 ng/ 2mL of
plasma along the 20 week-study (Supplementary Figure
2A-C). In these DNA samples, and as expected, we did
not detect wild type nor mutant GNAQ/11 ctDNA of
human origin at the time of inoculation (Fig. 3D). In
contrast, we detected mutated GNAQ ctDNA fragments
in groups 1 and 2, and mutated GNA11 ctDNA frag-
ments in group 3 as early as 4 weeks and 6 weeks post-
inoculation, respectively (Fig. 3 A-D), confirming the
potential of our assay to screen for different UM specific
mutations in vivo. Interestingly, in group 1, while ctDNA
was first detected 24 days after cell inoculation, in all the
animals intraocular tumors were detected clinically later,
on average 31.4 days post- cell inoculation, suggesting
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that ctDNA was an earlier biomarker of tumor forma-
tion compared to clinical imaging. In addition, in group
2, detection of ctDNA was highest at around 6 weeks;
however, levels decreased steadily and significantly
afterwards until animal euthanasia (Fig. 3B and D). De-
creased levels of ctDNA were concomitant with the
shrinkage of ocular tumors that were no longer visible
(like in rabbits G2:R2 (i.e. rabbit #2 in group 2), G2:R3,
and G2:R4) or very small (like in rabbits G2:R1 and G2:
R5) at autopsy (Fig. 3B and D). These observations cor-
related with the arrest of CsA administration, suggest-
ing the potential of our assay to monitor for disease
progression. In group 3, where ctDNA was not detected
before the 6th week, ocular tumors were detected at
the 6th or 8th weeks (Fig. 3C and D), suggesting again
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Fig. 1 Wildtype and mutant cfDNA were accurately detected in human UM cell line conditioned medium. A. Representative 2D fluorescence amplitude plots
of DNA extracted from conditioned medium (Cond. Media; cfDNA) and cells (genomic DNA). GNAQ and GNA11mutant DNA-positive droplets are shown in
blue (FAM channel), wild type DNA-positive droplets are represented in green (HEX channel), droplets positive for both wild type and mutant targets are
shown in orange, and the negative droplets are shown in black. B. Copy numbers of wild type and mutant cfDNA in UM cells conditioned medium. Data are
shown as number of molecules per mL of medium (mean +/− SD, n=3 independent experiments). C. Table summarizes ctDNA (molecules/mL) isolated from
condicionated medium and total DNA derived from cells and conditioned medium
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formation and a valuable tool to monitor UM progres-
sion. Overall, and by using Spearman correlation ana-
lyses, while no correlation was found between total
DNA (not tumor specific) and ctDNA or tumor size
(r = − 0.045, P = 0.63, or r = − 0.149, P = 0.39, respect-
ively) (Supplementary Figure 2F and G), we found a sig-
nificant positive correlation between ctDNA level and
tumor size in all the rabbits (r = 0.60, P < 0.0001), and a
negative correlation between ctDNA level and body
weight (r = − 0.37, P < 0.0001) (Fig. 3E), suggesting that
the correlation of blood ctDNA levels with tumor
growth was specific to DNA originating from ocular
UM tumor cells (i.e. ctDNA).
Taken together, these data bring strong evidence that
blood biopsy screening for human mutated GNA11/Q
ctDNA biomarkers is a valuable and feasible tool for the
early diagnosis of UM and the monitoring of disease
progression.
Fig. 2 A human UM rabbit model was used to validate the detection of mutated ctDNA in liquid biopsies. A. Overview of the developed human UM
xenograft model and animal follow-up procedures. For more details, see Material and Methods section. CsA; Cyclosporine A. B. Representative
fundoscopy and ultrasound images taken at tumor formation, and post-mortem photographies of dissected eyes (scale bares: 5 mm)
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Fig. 3 (See legend on next page.)
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UM-derived ctDNA detected in the aqueous humor
correlated with tumor size and progression
In parallel to the analyses done on blood biopsies, we
sought to determine whether UM ctDNA could be de-
tected in the aqueous humor (AH) of grafted animals.
An AH paracentesis was conducted in rabbits from
groups 1 and 2, then samples were analyzed for the pres-
ence of mutated GNAQ ctDNA. As expected, no detect-
able levels of UM ctDNA were found at the time of UM
cell inoculation. In contrast, we detected mutated GNAQ
ctDNA at the second sampling (weeks 5–8, range 0–4
molecules/mL) in both groups. Interestingly, at the third
sampling (weeks 18–19), we still detected mutated
GNAQ ctDNA in the AH of rabbits from group 1 (range
1–3 molecules/mL), while we observed a sustained de-
crease in the AH of rabbits from group 2 with only min-
imal detectable traces (Fig. 3F and G). Using Spearman
correlation analyses, we did not find any correlation be-
tween total DNA (not tumor specific) and ctDNA or
tumor size (Supplementary Figure 2H and I). In contrast,
we observed a significant and positive correlation be-
tween mutated GNAQ ctDNA level (tumor specific) and
tumor size (r = 0.71, P < 0.0001) and a negative correl-
ation between mutated GNAQ ctDNA level (tumor spe-
cific) and the body weight (r = − 0.33, P = 0.07) (Fig. 3H
and I). These data suggest that the AH is another bio-
logical source of ctDNA that can be used for the man-
agement of UM patients.
Mutant GNA11/Q ctDNA was detected in patient blood
biopsy and correlated with the degree of lesion
malignancy
GNAQ/11 mutations are present in more than 90% of
UM cases and, although not sufficient, they are thought
to be initiating events of the disease [10, 11]. As our
assay was able to detect these mutations in an in vivo
human UM rabbit model and correlated with disease
burden, we applied this strategy to clinical samples to
get more insight on its validity to screen for UM and
stratify patients presenting with ocular nevi (Tables 2, 3
and 4). In addition, for cases that were negative for
GNAQ/11 mutant DNA, we verified the presence of
PLCB4 and CYSLTR2 mutant ctDNA. As expected, all
analyzed samples (from 14 primary UM patients, 16 pa-
tients with choroidal nevi and 15 disease-free healthy
controls) were positive for wild type GNAQ, GNA11,
PLCβ4, CYSLTR2 ctDNA copies (Supplementary Figure
3A and Supplementary Figure 4). In addition, in contrast
to patient (UM and nevi) donors, none of the 15 healthy
control samples contained mutated GNAQ/11, PLCβ4,
CYSLTR2 ctDNA (Fig. 4A, B, and E, Supplementary
Figure 4).
We then focused our analyses first on blood biopsies
drawn from UM patients. Mutant GNAQ, GNA11 or
PLCβ4 ctDNA copies were detected in all 14 primary
UM patients. We found that these mutations were
present in a mutually exclusive manner and with fre-
quencies in the range of previously published data (i.e. 9
patients (64%) having a GNA11 mutation (range, 0.7–
26.4 molecules/mL), 4 patients (29%) having a GNAQ
mutation (range, 3.1–31.4 molecules/mL) and 1 (7%)
having a PLCβ4 mutation (2.1 molecules/mL) (Fig. 4A,
Supplementary Figure 4) [10, 11]. We did not observe
any correlation between the levels of ctDNA and the age
of patients or total DNA amounts (r = − 0.13, P = 0.48,
r = 0.07, P = 0.34, respectively) (Supplementary Figure 3B
and C).
We searched for a relationship between the levels of
mutated ctDNA copies and tumor stage. We found a
positive and significant correlation between the AJCC
classification and %FA (r = 0.69, P = 0.008) (Fig. 4C (left
panel) and Table 3) [39]. In addition, and although not
significant, we observed a correlation between the tumor
thickness and the %FA (r = 0.38, P = 0.079) (Fig. 4C
(right panel) and Table 3). These data suggest that our
assay combined to a blood biopsy is valuable to screen
for patients with UM lesions and to monitor for disease
aggressiveness.
We then sought to determine the pattern of mutated
GNAQ/11 ctDNA in the blood of patients presenting
with premalignant choroidal nevi. In this cohort, we re-
cruited 16 patients, and blood samples were processed
(See figure on previous page.)
Fig. 3 Mutated ctDNA plasma and aqueous humor levels mirrored the pattern of intraocular disease behavior in rabbits. A-C. Kinetics of the
levels of mutated ctDNA in rabbit plasma (left Y-axis) and tumor size categories (right Y-axis) following ocular inoculation of 92.1 cells (A and B;
Groups 1 and 2) or MP41 cells (C; Group 3). The legend for all panels is shown on the top A panel. D. Table shows the number of ctDNA
molecules/mL in rabbit plasma at inoculation (week 0), weeks: 4, 6, 8, 10, 12, 14, 16, and at euthanasia. E. Mutated plasma ctDNA levels were
plotted against tumor size categories (left panel) or rabbit body weight (right panel). Significant positive or negative correlations were
found between ctDNA levels and size categories (r = 0.60, P < 0.0001) or body weight (r = − 37, P < 0.0001). F-G. Kinetics of the levels of
mutated ctDNA in rabbit aqueous humor (left Y-axis), and tumor size categories (Cat) (right Y-axis) in animals inoculated with 92.1 cells
(F. Group 1, G. Group 2). H. Table shows ctDNA molecules/mL from aqueous humor at inoculation, weeks 5–8, and euthanasia. I. Top
panel: Mutated ctDNA aqueous humor levels were plotted against tumor size categories, which displayed a significant positive correlation
(r = 0.713, P < 0.0011). Bottom panel: Mutated ctDNA levels were plotted against rabbit body weight; no correlation was found (r = − 0.33,
P = 0.074). SD: Standard deviation
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Age at blood draw (years) Mean (SD) 60.1 (15.14)
Age at diagnosis (years) Mean (SD) 51.64 (15.35)
Follow-up (months) Mean (SD) 103 (77.8)
Location Choroid 13
Iris 1





Age at blood draw (years) Mean (SD) 65.6 (13.6)
Age at diagnosis (years) Mean (SD) 62.53 (11.24)
Follow-up (months) Mean (SD) 67.2 (61.8)
Location Choroid 15
Iris 1
Lesion size (mm) Mean (SD) Base 3.1 (1.5)
Thickness 1.6 (0.8)
Risk factors 7
No risk factors 9
Healthy individuals Number 15
Age at blood draw (years) Mean (SD) 30.2 (7.4)
F/U follow up. SD standard deviation
Table 3 UM patients characteristics
Code LB Sex Age (Y) Location ctDNA FA Lesion T category, AJCC classification FU Rx
21 F 70 Choroid 4.3 9.5 3 × 10 × 9 2 77 P
22 F 60 Choroid 2.8 3.7 9 × 1.9 × 5.7 4 50 P
27 F 68 Choroid 3.0 8 9.7 × 9 × 3.3 2 39 P+
28 F 48 Choroid 1.9 2.8 7.5 × 5.5 × 2.1 1 260 TT
29 M 62 Iris 12.8 2.7 3.4 × 3.8 × 1.3 1 37 PR
30 M 69 Choroid 2.3 17 16 × 16 × 8 3 61 P+
31 M 85 Choroid 29.3 33 9.5 × 8.5 × 3.1 3 229 P
32 M 63 Choroid 2.1 2.6 11.5 × 12 × 2.8 1 190 P+
33 F 82 Choroid 26.4 7 2.2 × 1 × 1 2 37 P+
36 M 37 Choroid 31.6 3.1 13.3 × 10.9 × 5 2 1 P
40 F 38 Choroid 3.2 1.6 10.7 × 8.5 × 3.0 1 92 SR
41 M 71 Choroid 9.8 13.5 8.2 × 8.7 × 4.3 2 164 P
42 F 38 Choroid 0.7 4 13 × 9.5 × 2.3 2 55 P+
43 M 51 Choroid 9.0 5 8.4 × 9.1 × 2.8 1 150 P
+ = anti-VEGF treatment; AJCC AJCC classification; ctDNA (molecules/ml); FA percentage of fractional abundance; FU follow-up time (months); Lesion Lesion size
(small diameter x large diameter x thickness) (in mm); P Plaque radiotherapy; PR Proton beam radiotherapy; Rx Treatment; SR Stereotactic radiosurgery; T T
category; TT Transpupillary thermotherapy
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to isolate either plasma (9 patients: LB20 – LB45) or
serum (7 patients: LB06 – LB12) (Fig. 4B and Table 4).
We categorized these patients according to the pres-
ence of clinical risk factors for melanoma transformation
by taking advantage of a systematic classification of clin-
ical and imaging features [40]. Of the 16 patients, 7 pa-
tients had at least 2 risk factors, and interestingly all
were positive for the presence of mutated GNAQ ctDNA
copies. Of the 9 patients with no risk factors, all, but
one, were negative for ctDNA (Fig. 4B and Table 4).
The positive patient (LB37) had bilateral nevi, one of
which was 1 mm thick. Notably, the levels of mutated
ctDNA positively and significantly correlated with the
presence of factors predisposing to nevus transformation
(r = 0.92, P < 0.0001) (Fig. 4D).
Moreover, while the levels of mutated ctDNA in pa-
tients having nevi with risk factors did not differ com-
pared to those in samples from the UM patient cohort,
they were significantly higher when compared to levels
in samples from patients having nevi with no risk factors
and from healthy individuals (P < 0.05) (Fig. 4E). This
highlights that a close follow-up of the levels of mutated
ctDNA in patients with choroidal nevi may be beneficial
for the early detection of potential transformation into
UM lesions. Altogether, our data bring evidence that
blood-based liquid biopsy screening for UM-specific mu-
tated ctDNA may be a new tool for the early UM diag-
nosis, the staging of lesion malignancy and the
monitoring of disease progression.
Discussion
Although rare, UM remains the most common primary
ocular cancer in adults and is associated with a high
mortality rate [4]. The disease often develops asymptom-
atically and is diagnosed following a routine ophthalmic
examination or as a result of following up patients with
choroidal nevi [1–3]. This argues for the development of
new quantitative tools to screen for patients at risk of
developing the disease [22]. By using biological analytes,
mainly blood, liquid biopsy has been investigated as a
strategy to detect and monitor cancer progression, re-
currence, and response to treatment [23]. Many circulat-
ing biological materials have been proposed as a readout
of tumor status, of which mutated ctDNA has gained
much attention [41, 42]. The presence of specific gene
mutations, like in GNAQ and GNA11, were proposed as
predisposing risk factors for UM development [10, 11].
As ctDNA is present at very low levels in the circulation,
a highly sensitive and specific assay to detect mutated
GNAQ and GNA11 moieties in patient blood is needed
[32]. In this study, we combined a blood-based liquid bi-
opsy and the sensitive ddPCR assay to conduct specific
UM-derived ctDNA screening [43]. We set the validity
of the analysis using cfDNA from cultures of human
UM cells, verified its clinical value in a human UM
xenograft rabbit model, and applied it to clinical samples
to correlate ctDNA levels to UM patients and patients
with choroidal nevi. In summary, we bring evidence that
blood biopsy permits the screening of UM-shed mutated
Table 4 Characteristics of patients with nevi
Code LB Sex Age (Y) Location ctDNA FA B TN FU RX RF Notes
06 F 73 Choroid 0 0 3 Flat 81 – 0 –
07 M 72 Choroid 0 0 NA Flat 53 – 0 –
08 M 80 Choroid 0 0 2 Flat 141 – 0 –
09 M 79 Choroid 0 0 1.5 1.3 170 – 0 –
10 M 83 Choroid 0 0 3 Flat 182 – 0 Bilateral
11 M 64 Choroid 0 0 4 Flat 48 – 0 –
12 F 70 Iris 0 0 2.4 0.6 170 – 0 –
20 M 77 Choroid 3.1 1.1 1.8 NA 11 + 4 OP, S, F, PP
23 F 57 Choroid 12.1 1.8 NA NA 5 + 4 T, OP, F, S
24 F 68 Choroid 4.3 0.7 NA 2.3 15 – 3 PP, F, T
25 F 35 Choroid 13.3 28 4.5 2.47 13 + 4 F, S, T, G
34 M 80 Choroid 2.3 0.6 NA NA 9 – 2 OP, F
35 F 60 Choroid 0 0 2 Flat 12 – 0 –
37 F 47 Choroid 1 7 7 OD: Flat.
OS: 1
82 – 0 Bilateral
38 F 45 Choroid 2.3 6 3.2 1.7 12 – 4 OP, F, PP, S
45 F 60 Choroid 4.4 1.8 NA 2.7 18 – 2 PP, T
+ = anti-VEGF treatment; B Basal diameter (mm); ctDNA (molecules/ml). F fluid; FA percentage of fractional abundance; FU follow-up time (months); G Growth; OP
orange pigment; PP peripapillary; RF number of risk factors; Rx Treatment; S visual symptoms; T thickness > 2mm; TN thickness (mm);
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ctDNA as a way of early diagnosis, malignancy burden
staging, and disease progression monitoring.
Liquid biopsy approaches using CTCs has been pro-
posed and applied in the context of UM, where CTCs
were found in 29 out of 40 UM patients (72%) at the
time of diagnosis and after treatment [44]. This is in
contrast to the 100% efficiency (14 out of 14 analyzed
UM patients) of UM mutant ctDNA detection we
Fig. 4 The levels of mutated ctDNA in UM patients and patients with uveal nevi correlated with the stage of disease progression and with the presence of risk
factors for malignant transformation, respectively. A. UM patients: levels of GNA11, GNAQ and PLCβ4mutated ctDNA (molecules/mL of plasma) are shown in
dark blue, red and green, respectively, and %FA of GNA11, GNAQ and PLCβ4 is shown in light color (the table shows the mutation status in the analyzed loci). B.
Nevi: levels of ctDNA molecules/mL of plasma (dark) and %FA (in light color) in patients (the table shows the mutation status in the analyzed loci). Note that in
all patients, only a GNAQmutation was detected. P:plasma. S:serum. C. Left panel: the %FA obtained with the UM samples were plotted against the T category
of the AJCC staging, which displayed a significant positive correlation (r = 0.69, P = 0.008). Right panel: The %FA obtained with the UM samples were plotted
against tumor thickness (mm); no correlation was found (r = 0.38, P = 0.079). D. The levels of mutated ctDNA in plasma samples obtained from patients with
nevi were plotted against the number of risk factors in every patients, which displayed a significant positive correlation (r = 0.92, P < 0.0001). E Left panel: Scatter
plot depicting the levels of mutated ctDNA in the plasma of UM patients and patients with nevi displaying or not risk factors for malignant transformation, and
serum of healthy blood donors. Note the increased levels of ctDNA that accompany increased risk factors. The table (on the right) depicts the comparisons
used and the levels of significance for differences (P value)
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reported in our present study. In addition, ctDNA has
been analyzed in UM samples using other assays (i.e.
ultradeep sequencing and bidirectional-
pyrophosphorolysis-activated polymerization technique),
but no clinical value has been reported [45]. Our patient
cohort presented a hotspot mutation in GNAQ (Q209P
and Q209L), GNA11 (Q209P and Q209L), or PLCB4
(D630Y), which have been reported in the majority
of UM cases. However, other hotspot mutations in those
genes should not be discarded. Moreover, until now, the
presence of ctDNA in patients with pre-malignant intra-
ocular nevi had not been investigated. Together, this
makes our study the first to investigate the presence of
ctDNA using initiating UM mutations in patients with
choroidal nevi and to report positive correlations be-
tween the levels of these mutated ctDNA, and both the
UM staging system and the clinical risk factor classifica-
tions [18, 35, 39, 40]. Importantly, since ddPCR requires
the prior knowledge of the specific point mutation [46],
it is not an ideal technique in cancer types with un-
known driver events or in which various point mutations
can be detected. However, in UM we were able to take
advantage of the high proportion of UM cases with a
mutually exclusive mutation in one of the four genes
assayed. ddPCR is high sensitive (i.e. 0.01% sensitivity: 1
mutant copy in 10,000 wild type gene copies) and it does
not rely on sequencing efforts, making the monitoring of
ctDNA in UM patients sensitive and inexpensive [31, 32,
46, 47].
In the UM rabbit model we conducted our assay antic-
ipated in situ detection of UM lesions. Indeed, we ob-
served an early presence of ctDNA days before standard
clinical imaging techniques detected ocular tumors. This
suggests that ctDNA screening in a blood biopsy may be
an effective biomarker for early disease development
when tumors are too small to be diagnosed by ophthal-
mological examination, such as fundoscopy. In addition,
we observed that mutant ctDNA levels in the AH corre-
lated with tumor burden, making it another analyte to
test during patient follow-up, although accessing it is
more invasive. This observation is supported by the find-
ing that cytokine expression patterns in the AH discrim-
inated between high- and low-risk UM patients [48].
During plaque brachytherapy implantation in UM pa-
tients, an anterior chamber paracentesis is a feasible and
safe procedure that can be performed [48, 49].
In our clinical study, we were unable to match the
blood biopsies to ocular tumor tissue biopsies to confirm
the mutational status and validate that we screened for
molecules deriving from UM tumors. This limitation
was overcome by the use of the UM animal model,
where the rabbits were inoculated with cells of known
mutations. In these experiments, we found the corre-
sponding parental mutations in the recovered ctDNA,
respective of the cell line used (92.1 vs. MP41). Overall,
in this animal model, our assay allowed us to monitor
disease progression (Fig. 3). Notwithstanding, a well-
designed study aimed to ensure matching of blood bi-
opsy and ocular lesion genotype in clinical samples is
still needed. Also, detecting ctDNA in a longitudinal
study can shed light into UM dynamics and progression.
A prospective study that enrolls patients from diagnosis,
monitoring throughout treatment, and follow up using a
single blood collection type, is needed and is currently
ongoing at our center.
We found that GNAQ and GNA11 mutated ctDNA is
present in a mutually exclusive manner and in frequen-
cies in the range of reported data for UM [10, 11]. Not-
ably, while GNA11 mutated ctDNA was more frequent
in samples from UM patients, only mutated GNAQ
ctDNA fragments were detected in samples from pa-
tients with nevi presenting with risk factors. Although
further samples are still required to deepen this observa-
tion, this suggests that GNA11 mutations are more com-
monly initiating events in de novo UM, while GNAQ
mutations trigger malignant transformation from pre-
existing nevi.
The incidence of choroidal nevi is likely underestimated,
as these nevi are usually only found on ophthalmic exami-
nations for other clinical reasons. Although nevi remain
generally stable over time, malignant transformation to-
wards melanoma increases with age and the appearance of
clinical risk factors [16–18, 40, 50]. In addition, equivocal
diagnosis of nevi with clinical risk factors that border onto
malignancy is challenging [20]. Hence, monitoring intraoc-
ular nevi using specific ctDNA is paramount for patient
follow-up. In our study, patients LB29 and LB33 were diag-
nosed with ocular nevi 3 and 4 years prior to the melanoma
diagnosis, respectively. Furthermore, samples with un-
detectable levels of ctDNA may carry other hotspot muta-
tions not included in this panel. We could not explore the
correlation between ctDNA levels and thickness or base
size in nevi lesions due to lack of information on medical
records. However, considering clinical risk factors, our data
in the nevi cohort suggest that ctDNA may indicate lesions
transforming to malignant melanoma. Given the non-
invasive and inexpensive nature of our testing, we propose
that patients with choroidal nevus are ideal candidates to
be monitored though such a liquid biopsy approach.
Preanalytical variables can influence the outcome of
cfDNA [51]. Biological factors (e.g. exercise, pregnancy,
inflammation, diabetes) affect the levels of cfDNA [23,
36]. Methodological variables can also impact the out-
come of cfDNA [51]. For example, differences in recov-
ery of DNA have been observed using different
commercial extraction kits. In this work, the QIAamp
CNA was used, which is considered as the gold standard
approach [52]. In addition, higher cfDNA amounts with
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increased number of wild type loci copies were recov-
ered from serum compared to plasma, likely due to the
release of DNA from the lysis of white blood cells that
occurs during clotting [51]. This is in line with our find-
ings that serum was enriched in wild type GNAQ/11
ctDNA fragments compared to plasma samples (Supple-
mentary Figure 3G). This observation may explain the
lack of detection of ctDNA in all serum samples despite
having higher cfDNA levels, making the use of plasma
more likely suitable for liquid biopsy-based platforms to
screen for mutated ctDNA.
Half of UM patients will develop metastatic disease
many years and even decades after primary ocular tumor
diagnosis due to dormant micro-metastases foci [3, 4],
36 [53]. Blood-based biomarkers screening, originally de-
signed for cutaneous melanoma, have been tested in UM
patients, but have shown little promise [4, 24, 54, 55]. As
metastatic patients present higher ctDNA compared to
patients with primary disease, our assay may be used to
screen for patients at risk of UM metastasis [56].
Conclusion
Our study is of high importance to monitor UM patients
and individuals at risk of developing the disease. Liquid bi-
opsy is especially relevant to UM where classical tissue bi-
opsies are generally not used for diagnosis. As a
noninvasive strategy, its combination to sensitive and reli-
able technologies allows the monitoring of disease pro-
gression. By combining human UM cell culture and an
in vivo animal model, we established the proof of principle
for the validity of ddPCR to screen for specific UM mu-
tated ctDNA in clinical UM samples. We conclude that
patient plasma is an easily accessible milieu to track mu-
tated ctDNA for the early diagnosis and staging of the pa-
tients, and the monitoring of disease progression. Further
studies targeting the analysis of other UM mutations and
involving a greater number of primary and metastatic UM
patients, and patients with choroidal nevi are necessary,
and are currently in progress in our institution.
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